Skip to Main Content
Yuefan Wang

Yuefan Wang

Partner
Overview

Yuefan guides clients through complex corporate transactions, with a focus on the cannabis sector and private equity. Yuefan also advises on compliance with the new Corporate Transparency Act.

Yuefan has experience representing large corporations, multinational companies, and investors in mergers and acquisitions, joint ventures, equity financings, and complex commercial agreements in both the U.S. and China. Having worked extensively in the agribusiness, life sciences and energy industries, he currently focuses his practice on cannabis and industrial hemp. Clients appreciate his guidance through this ever-changing regulatory environment and the unprecedented opportunities of today’s market landscape.

Yuefan especially enjoys the intricacies of drafting complicated deal documents tailored to the particular business transaction envisioned by the client, instead of offering a one-size-fits all approach. 

Yuefan serves as co-chair of APISWANA, the firm’s Asian, Pacific Islander, Southwest Asian, and North African Employee Resource Group.

Industry

Services

Recognition

  • Best Lawyers: Ones to Watch® in America
    • Corporate Law, 2024 and 2025
  • 5280 Top Lawyer, 2023

Education

  • J.D., University of Texas School of Law
    • with honors
  • B.A., Vanderbilt University
    • magna cum laude
    • Psychology major, mathematics minor

Admissions

  • Colorado

Professional Memberships and Certifications

  • Legal Aid Foundation of Colorado, Board Member

Languages

  • Mandarin, fluent
  • Shanghainese, fluent


*Contact Yuefan to set up an in-person consultation by appointment in the Denver office.
2024 Pro Bono Contributor
Experience

Cannabis and Industrial Hemp

  • LivWell Holdings Inc., in its sale to PharmaCann Inc.
  • Los Sueños Farms, one of the largest outdoor cultivations in North America, in its $67 million sale to Curaleaf.
  • Medicine Man in its sale to Columbia Care.
  • The Health Center in its sale to a publicly traded special purpose acquisition company (SPAC).
  • Lightshade Labs in the acquisition of Frosted Leaf out of receivership for $3.5 million.
  • Lightshade Labs in a variety of acquisitions and sales of dispensaries and cultivations in Colorado.
  • Franklin Energy in its acquisition of Cultivate Energy Optimization.

Private Equity and Private M&A

  • Rallyday Partners in the acquisition of Pyx Health, a technology-enabled mental health services platform.
  • Rallyday Partners in a strategic investment in Power Technologies, LLC, the owners of Anywhere Cart, which is the market leader in charging carts, cabinets and accessories in the education space.
  • Rallyday Partners in a strategic investment in Performance Physical Therapy, a leading New England-based physical therapy platform.
  • TricorBraun in the acquisition of PBFY, one of the largest flexible packaging distributors in North America.
  • TricorBraun in the acquisition of Mark's Barrel Company, an industrial container reconditioning and recycling company.
  • Hong Kong fund of a major U.S. private equity firm in its bid for prominent business-to-business media company.
  • Chinese-German private equity fund in the acquisition of U.S. pharmaceutical company from a major U.S. private equity fund.
  • Electronics manufacturer partially owned by the Beijing municipal government in its acquisition of a U.S. semiconductor company. Assisted in Committee on Foreign Investment in the United States (CFIUS) filing for the transaction, which resulted in a rare approval for a Chinese acquirer.
  • Rosneft in its CFIUS filing with respect to the acquisition of certain energy assets from Morgan Stanley.

Healthcare and Life Sciences

  • Raleigh Ophthalmology in its strategic partnership with EyeSouth Partners.
  • Texan Eye and Eye LASIK Austin in their strategic partnership with Comprehensive EyeCare Partners.
  • A prominent Texas-based psychotherapy practice in its sale to a private equity firm.
  • A Wisconsin-based healthcare IT provider in its sale to a private equity firm.
  • Major U.S. pharmaceutical company in the spin-off of certain drug businesses, comprising physical assets, intellectual property (IP) and government licenses and approvals, to a Chinese pharmaceutical distributor.
  • Major U.S. medical devices manufacturer in its acquisition of a factory from a Chinese medical devices manufacturer.
  • Taiwanese healthcare investment fund in a transaction with a pioneering U.S. genomics company involving an investment in the U.S. parent company, along with the creation of a joint venture in Asia.

Take-Private

  • Special committee of a Chinese software and mobile applications company in a de-listing and going private transaction.
  • Management buyers in the de-listing and going private of a Chinese mobile games company.

Securities Filings

  • U.S. Securities and Exchange Commission (SEC) filings for a major Chinese investment fund's investment in a Chinese automotive services company. Advised client on SEC rules and prepared filings.
  • SEC filings in relation to various public mergers, including Form 8-K/6-K, proxy statements and Schedule 13E-3, and Schedule 13D.

Other

  • Orica in its acquisition of a mining software company.
  • A prominent Las Vegas-based restauranteur in a strategic joint venture.
White Papers | December 15, 2023
Corporate Transparency Act Guide

On January 1, 2024, the Corporate Transparency Act (CTA) will go into effect, and if your business is deemed to be a Reporting Company under the CTA, the clock will begin ticking on new federal reporting obligations.

News Releases | February 28, 2022
Husch Blackwell Guides LivWell in Sale to PharmaCann
News Releases | December 06, 2021
Husch Blackwell Elects 36 to 2022 Partnership Class
Outside the Office

A transplant to Colorado, Yuefan loves all that the state has to offer, especially skiing and camping.  In his other free time, Yuefan enjoys assembling mechanical keyboards, collecting fountain pens, painting, and traveling.